MedTrace Logo

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

NCT03508739 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-09-10

No results posted yet for this study

Summary

Type 2 diabetes is common, increases in prevalence with age, and patients with diabetes have an increased risk of cardiovascular disease. A relatively new cardiovascular medication currently used for the treatment of heart failure in the United States inhibits an enzyme that breaks down a variety of signaling hormones. This clinical trial tests if it may also be a target for the treatment of diabetes by decreasing the breakdown of a hormone that increases insulin release after a meal.

Conditions

  • Diabetes Mellitus, Type 2
  • Pre-diabetic
  • Hypertension
  • Elevated Blood Pressure

Interventions

DRUG

Sacubitril/Valsartan 200mg (blinded)

study day 2 for AB and study day 3 for BA

DRUG

Valsartan 160mg (blinded)

study day 3 for AB and study day 2 for BA

Sponsors & Collaborators

Principal Investigators

  • Jessica R Wilson, MD, MSCI · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2026-06-01
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03508739 on ClinicalTrials.gov